Provided by Tiger Trade Technology Pte. Ltd.

Alkermes PLC

41.75
+1.212.98%
Post-market: 41.750.00000.00%19:30 EDT
Volume:2.42M
Turnover:100.91M
Market Cap:7.00B
PE:107.54
High:41.96
Open:41.03
Low:40.32
Close:40.54
52wk High:55.67
52wk Low:27.00
Shares:167.76M
Float Shares:155.00M
Volume Ratio:0.95
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3882
EPS(LYR):1.43
ROE:3.85%
ROA:4.20%
PB:3.87
PE(LYR):29.20

Loading ...

Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02

Reuters
·
10 hours ago

Alkermes (ALKS), What Is Behind The Fresh Attention?

Simply Wall St.
·
Yesterday

Alkermes (ALKS) Gets a Hold from Goldman Sachs

TIPRANKS
·
Sep 24

Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says

MT Newswires Live
·
Sep 22

Analysts’ Opinions Are Mixed on These Healthcare Stocks: AnaptysBio (ANAB), Alkermes (ALKS) and Iradimed (IRMD)

TIPRANKS
·
Sep 22

Alkermes Plc : Jefferies Raises Target Price to $83 from $78

THOMSON REUTERS
·
Sep 22

Alkermes data show measurable improvements in ADHD, says H.C. Wainwright

TIPRANKS
·
Sep 22

Alkermes Price Target Maintained with a $62.00/Share by Needham

Dow Jones
·
Sep 21

Alkermes Plc : Baird Raises Target Price to $61 from $58

THOMSON REUTERS
·
Sep 21

Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell

MT Newswires Live
·
Sep 21

U.S. Stocks on the MOVE-Accenture, Arhaus, Alkermes

Reuters
·
Sep 21

Alkermes jumps 8% to $46.99 after Phase I adult ADHD data

TIPRANKS
·
Sep 21

S&P 500 Futures Rise in Premarket Trading; Ingram Micro, Kite Realty Group Trust Lag

Dow Jones
·
Sep 21

Alkermes Shares Rise 6.5% Premarket After Positive Results from Early-Stage Study of Adhd Drug

THOMSON REUTERS
·
Sep 21

Alkermes announces Phase 1b results of ALKS 7290 in ADHD

TIPRANKS
·
Sep 21

Alkermes Reports Positive Phase 1b Proof-of-Concept Data for ALKS 7290 in Adult ADHD

Reuters
·
Sep 21

Alkermes -Alks 7290 Generally Well Tolerated at All Doses in Healthy Volunteers and Adults with Adhd

THOMSON REUTERS
·
Sep 21

Alkermes Announces Positive Phase 1B Results Demonstrating Clinical Proof-of-Concept for Alks 7290 in Adults with Attention-Deficit Hyperactivity Disorder (Adhd)

THOMSON REUTERS
·
Sep 21

Alkermes - Phase 2 Study of Alks 7290 in Adults with Adhd Enrolling, Data Expected in 2027

THOMSON REUTERS
·
Sep 21

Alkermes Files Form 3 for Director Anne Clem Whitaker`

Reuters
·
Sep 19